SynAct Pharma AB (SYNACT)
Free
No email, no account, no signup.
Pulling latest news for SynAct Pharma AB…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Biotechnology, inflammatory diseases
Market Cap
$91M
We're already tracking SynAct Pharma AB — here are the latest events we've registered
Recent News
- In April 2026, SynAct Pharma published its 2025 Annual Report and announced the dosing of the first patients in the Phase 2 RESOVIR-2 study. Topline data from the Phase 2b ADVANCE study is expected in June 2026. Management also confirmed that the company's financial runway is secured into the third quarter of 2027.
Want to know how this news affects SynAct Pharma AB? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of SynAct Pharma AB will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.